全文获取类型
收费全文 | 1849篇 |
免费 | 130篇 |
国内免费 | 45篇 |
出版年
2023年 | 17篇 |
2022年 | 40篇 |
2021年 | 47篇 |
2020年 | 38篇 |
2019年 | 47篇 |
2018年 | 47篇 |
2017年 | 36篇 |
2016年 | 62篇 |
2015年 | 56篇 |
2014年 | 85篇 |
2013年 | 84篇 |
2012年 | 63篇 |
2011年 | 111篇 |
2010年 | 54篇 |
2009年 | 79篇 |
2008年 | 97篇 |
2007年 | 106篇 |
2006年 | 82篇 |
2005年 | 93篇 |
2004年 | 88篇 |
2003年 | 67篇 |
2002年 | 63篇 |
2001年 | 40篇 |
2000年 | 45篇 |
1999年 | 53篇 |
1998年 | 47篇 |
1997年 | 43篇 |
1996年 | 52篇 |
1995年 | 40篇 |
1994年 | 44篇 |
1993年 | 39篇 |
1992年 | 36篇 |
1991年 | 22篇 |
1990年 | 21篇 |
1989年 | 7篇 |
1988年 | 3篇 |
1987年 | 6篇 |
1986年 | 4篇 |
1985年 | 4篇 |
1984年 | 5篇 |
1983年 | 3篇 |
1982年 | 6篇 |
1981年 | 5篇 |
1980年 | 23篇 |
1979年 | 1篇 |
1978年 | 5篇 |
1976年 | 2篇 |
1974年 | 2篇 |
1973年 | 1篇 |
1972年 | 2篇 |
排序方式: 共有2024条查询结果,搜索用时 140 毫秒
41.
Wim Van de Vrie Sylke A. M. Van der Heyden Eric E. O. Gheuens Amelie M. Bijma Ernst A. De Bruijn Richard L. Marquet Allan T. Van Oosterom Alexander M. M. Eggermont 《Cancer immunology, immunotherapy : CII》1993,37(5):337-342
The development of resistance to anticancer drugs urges the search for different treatment modalities. Several investigators have reported the concomitant development of drug resistance and resistance to natural killer (NK), lymphokine-activated killer (LAK) or monocyte/macrophage cell lysis, while others described unchanged or even increased susceptibility. We investigated this subject in the rat colon carcinoma cell line, CC531-PAR, which is intrinsically multidrug-resistant (MDR), and in three sublines derived from this parental cell line: a cell line with an increased MDR phenotype (CC531-COL), a revertant line from CC531-COL (CC531-REV), which demonstrates enhanced sensitivity to anticancer drugs of the MDR phenotype, and an independently developed cisplatin-resistant line (CC531-CIS). In a 4-h51Cr-release assay we found no difference in susceptibility to NK cell lysis. No significant differences in lysability by adherent LAK (aLAK) cells were observed in a 4-h assay. In a prolonged 20-h51Cr-release assay an enhanced sensitivity to aLAK-cell-mediated lysis was observed in the revertant, P-glycoprotein-negative cell line and in the cisplatin-resistant cell line (CC531-CIS). None of the cell lines was completely resistant to lysis by aLAK cells. Therefore, a role for immunotherapy in the treatment of drug-resistant tumors remains a realistic option. 相似文献
42.
Intratumoral interleukin-2 immunotherapy: Activation of tumor-infiltrating and splenic lymphocytes in vivo 总被引:5,自引:1,他引:4
Steven M. Dubinett Lisa Patrone Jeffery Tobias Alistair J. Cochran Duan-Ren Wen William H. McBride 《Cancer immunology, immunotherapy : CII》1993,36(3):156-162
Direct intratumoral injection of interleukin-2 (IL-2) was evaluated in a murine model. Balb/c mice received 5 × 104 Line 1 alveolar carcinoma cells (L1C2) by subcutaneous injection. On the third day following tumor implantation, mice received injections of IL-2 (5 × 103–5 × 104 units) or diluent twice daily, either by i. p. or intratumoral injection, 5 days/week for 3 weeks. Intratumoral injection of 5 × 104 units IL-2 significantly reduced tumor volume (P <0.05 versus control), increased median survival time (P = 0.0001), and resulted in a 23.5% cure rate (P = 0.008). There were no long-term survivors in the other treatment groups. Both tumor-infiltrating lymphocytes (TIL) and splenic lymphocytes isolated directly from IL-2-treated mice demonstrated enhanced cytolytic activity compared to diluent-treated controls. To determine whether non-T-cell-mediated antitumor responses were active in our model, intratumoral immunotherapy was evaluated in athymic Balb/cnu/nu mice. In order to decrease the recruitment of lymphocyte precursors, nude mice were splenectomized and received cyclophosphamide prior to tumor injection and IL-2 therapy. Intratumoral IL-2 immunotherapy also significantly decreased tumor volume in these immunodeficient mice (P <0.02), but did not lead to long-term survival. We conclude that both TIL and splenic lymphocytes are activated in vivo in response to intratumoral IL-2 immunotherapy, suggesting that intratumoral therapy with IL-2 activates both local and systemic antitumor responses.Supported by the Tobacco-Related Disease Research Program of the University of California, the Cancer Research Coordinating Committee, the Jonsson Cancer Center Foundation, and Veterans Administration Medical Research Funds 相似文献
43.
Naoko Morioka Lan L. Sze Donald L. Morton Reiko F. Irie 《Cancer immunology, immunotherapy : CII》1993,37(5):316-322
Fraction 4 (F4), a protein fraction isolated from aged garlic extract, enhanced cytotoxicity of human peripheral blood lymphocytes (PBL) against both naturalkiller (NK)-sensitive K562 and NK-resistant M14 cell lines. Although F4 treatment alone increased cytotoxicity, the effect was more remarkable when F4 was administered together with suboptimal doses of interleukin-2 (IL-2); combination treatment of 5 g/ml F4 plus 10 U/ml IL-2 for 72 h generated lymphokine-activated killer activity equivalent to that produced by 100 U/ml IL-2 alone against M14. F4 enhanced IL-2-induced proliferation and IL-2 receptor (Tac) expression of PBL without significant increase of IL-2 production. The enhancement of cytotoxicity both by F4 alone and by F4 plus IL-2 was abolished by anti-IL-2 antibody. F4 also enhanced concanavalin-A(ConA)-induced proliferation of PBL. Radiolabeled-ConA binding assays revealed that F4 treatment greatly augmented the affinity and slightly increased the number of ConA binding sites in PBL. F4 also enhanced ConA-induced IL-2 receptor (Tac) expression and IL-2 production of PBL. Anti-IL-2 antibody inhibited the effect of F4 on ConA-induced proliferation. These data suggest that IL-2 is involved in augmentative effects of F4. Our results indicate that F4 is a very efficient immunopotentiator and may be used for immunotherapy. 相似文献
44.
Yasunari Nakashima Seiji Mita Kiyoshi Takatsu Michio Ogawa 《Cancer immunology, immunotherapy : CII》1993,37(4):227-232
The antitumor activity of peritoneal exudate cells (PEC) induced by murine interleukin-5 (mIL-5) was examined using Meth-A sarcoma cells transplanted into the peritoneal cavity of mice. Although in vitro treatment of Meth-A sarcoma cells with mIL-5 did not result in inhibition of their growth, treatment of mice intraperitoneally with mIL-5 (1 g/day) from day –5 to +5 (tumor cells were inoculated on day 0) led to a significant increase in survival or even rejection of tumor cells. This antitumor effect depended on the dose of mIL-5. Interestingly, there was identical therapeutic activity when the protocol of days –10 to –1 was used as opposed to –5 to +5. In addition, post-treatment with mIL-5 from day +1 to +10 was ineffective. This suggests that the therapeutic activity of IL-5 is largely prophylactic. Under the former condition, the number of PEC was found to increase over 50-fold when compared to levels in control mice. Moreover, the antitumor effect of mIL-5 was completely abolished by subcutaneous injection of anti-mIL-5 monoclonal antibodies. The treatment of mice injected intraperitoneally with human IL-2 also resulted in an increase in survival. Winn assay experiments using PEC recovered from mIL-5-treated mice (1g/day, from day –10 to –1) revealed that these PEC could mediate antitumor activity against Meth-A sarcoma cells. Furthermore, when the cured mice were re-injected with Meth-A sarcoma cells or syngeneic MOPC 104E cells, they could reject Meth-A sarcoma cells but not MOPC 104E cells, indicating that immune memory had been generated. These results suggest that IL-5 augumented the PEC tumoricidal activity but we have no indication that the tumoricidal activity was mediated through a mIL-5-dependent mechanism. 相似文献
45.
CD4+8– T lymphocytes with potent antitumor activity in vivo were obtained in peritoneal exudate cells by immunizing mice with irradiated MM48 tumor cells admixed with OK-432. These immune CD4+ T cells were used in adoptive immunotherapy for prevention of lymph node metastases after removal of the primary tumor. Complete cure of metastases was obtained by adoptive transfer of CD4+ T cells admixed with irradiated MM48 tumor cells, but not by CD4+ T cells alone. To analyze the curative effect of admixing tumor cells on the prevention of metastases, a model of 1-day tumor inoculated with macrophages was used. Administration of immune CD4+ T cells alone resulted in the regression of local tumor in more than half of the mice, although all of them eventually died of lymph node metastases. On the other hand, adoptive transfer of immune CD4+ T cells plus irradiated tumor cells resulted in the complete regression of local tumors in all the mice, which survived without any sign of metastasis. The curative effect of the immune CD4+ T cells obtained by admixing irradiated tumor cells was tumor-specific. Macrophages induced by OK-432 (tumoricidal), implanted together with tumor, assisted tumor regression more than did macrophages elicited by proteose peptone (nontumoricidal) in the same adoptive transfer system. Administration of recombinant interleukin-2 instead of stimulant tumor cells did not enhance, but rather eliminated the constitutive antitumor activity of CD4+ T cells. On the other hand, exogenous recombinant interleukin-1 was more effective in the enhancement of antitumor activity of the CD4+ T cells as compared with stimulant tumor cell administration. In this case, the activating states of macrophages at the implanted tumor site had no influence on the therapeutic efficacy. A possible role of macrophages for induction of tumor-specific cytotoxic T cells that were mediated by tumor-specific CD4+ T cells is discussed. 相似文献
46.
The immunogenicity of recombinant interleukin-2 (rIL-2, EuroCetus, Amsterdam, Netherlands) was studied in seventy-six patients receiving different subcutaneous immunotherapy regimens. Patients presented with progressive metastatic renal cell carcinoma, malignant melanoma, colorectal cancer, B-cell lymphoma, and Hodgkin's disease. An enzyme immunoassay (EIA) was employed to screen patients for development of non-neutralizing antibodies against rIL-2, antibody specificity was confirmed by a standard Western blot. Neutralizing serum activity against rIL-2 was detected using a standard CTLL mouse proliferation assay. Additionally, serum levels of soluble interleukin-2 receptors and lymphocyte subsets expressing the CD56 natural killer (NK) associated antigen were measured.In a proportion of approximately 35% to 90% of the patients treated, non-neutralizing antibodies against rIL-2 could be detected after all treatment courses were evaluated. Antibodies were of the IgG, IgM, IgA and IgD subtypes. None of the 76 patients exhibited serum neutralizing activity after one treatment course. Five patients exhibited neutralizing anti-rIL-2 serum activity after two or more treatment courses of systemic rIL-2. In three of these patients, antibodies neutralized both recombinant and natural IL-2. Patients developing neutralizing anti-rIL-2 antibodies, exhibited significantly lower serum sIL-2 receptor levels upon the emergence of serum neutralizing activity than patients without antibody. Additionally, NK cell associated CD56 positivity was significantly lower in patients who exhibited neutralizing anti-rIL-2 serum activity than in patients who did not. A significant decrease in levels of soluble IL-2 receptors and CD56 NK cell positivity was observed, when comparing values prior to and after onset of serum neutralizing activity against rIL-2. However, while emergence of neutralizing antibodies to rIL-2 diminished rIL-2 induced biological activation, it did not coincide with abrogation of treatment response.Abbreviations rIL-2
recombinant interleukin-2
- EIA
enzyme immuno assay
- rIFN-2
recombinant interferon- 2 相似文献
47.
潘氏闭壳龟(Cuora pani)是中国特有种,国家二级重点保护野生动物。由于非法贸易加之栖息地破坏等,其野外种群数量十分稀少。本研究旨在利用线粒体基因与核基因标记揭示潘氏闭壳龟的遗传多样性和遗传结构,以期为中国潘氏闭壳龟的种群保护和管理提供科学依据。本次共研究14只潘氏闭壳龟个体,其中,6只原产地为四川广元,8只产地未知。结果表明,在14只潘氏闭壳龟样本中鉴定出Cyt b单倍型、ND4单倍型和R35单倍型各2个,且均有1个新单倍型;Cyt b、ND4和R35基因单倍型多样性分别为0.440、0.143和0.154,核苷酸多样性分别为0.000 41、0.000 19和0.000 63;各单倍型的平均遗传距离(p)均小于0.01。基于三个基因联合数据集的系统发育分析表明,潘氏闭壳龟与金头闭壳龟(C.aurocapitata)互为单系进化支,且中性检测和核苷酸错配分析显示,潘氏闭壳龟群体近期历史上可能未经历群体扩张事件。潘氏闭壳龟群体遗传多样性低,种内变异小,群体应对环境变化的能力低,建议应加强对中国潘氏闭壳龟野外种群的基础研究和保护力度,同时规范人工繁殖,以避免近亲繁殖和种群衰退。 相似文献
48.
采用HPIEC应用CM交换柱分离纯化E.coli工程菌表达的rIL-2,与空气氧化复性相比较,又有1倍以上的变性rIL-2在色谱过程中得到复性,且溶液pH影响rIL-2的复性和纯化效果:pH7.0时rIL-2复性率高于pH8.0时,但纯度明显低于pH8.0时分离的rIL-2. 相似文献
49.
用自制的氨基PEG化试剂rIL-2进行化学修饰,研究了试剂浓度,溶液pH,反应时间等与PEca-rIL-2产率及IL-2活性保持之间的关系,建立了一套获得稳定修饰度的PEG-rIL-2的方法。研究发现,反应时间跟修饰度关系不大;溶液pH对修饰度有一定的影响,中性pH以上反应都可进行;而试剂浓度直接决定修饰度的高低,过量越多,修饰度越高,而生物活性保留也越低;但低度修饰,对活性几乎没有影响,可保留活性在95%左右。 相似文献
50.